Abstracts tagged "Patient reported outcomes"

Abstract Number: 1210 • ACR Convergence 2023
Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis
Fahad Ahmed¹, Syed M. Rahman², Sarah Trent³, Lap Pham³, Nashwah Memon⁴, Hannah Chung³ and Adel Haque⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³PA Dermatology Partners, Philadelphia, PA, ⁴Lake Erie College of Osteopathic Medicine, Bradenton, FL, ⁵Jefferson Health - Northeast, Philadelphia, PA
Background/Purpose: Data suggest that patient satisfaction with drug therapy in psoriasis (Pso) and psoriatic arthritis (PsA) is associated with treatment compliance and, ultimately, disease response.…
Abstract Number: 1360 • ACR Convergence 2023
Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort
Yvette Meissner¹, Bernhard Eickhoff¹, Cornelia Glaser², Joerg Henes³, Jutta Richter⁴, Susanna Spaethling-Mestekemper⁵, Christof Specker⁶, Rebecca Fischer-Betz⁴ and Anja Strangfeld¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology University Medical Center Freiburg, Freiburg, Germany, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Düsseldorf, Germany, ⁵Rheumapraxis Muenchen, Muenchen, Germany, ⁶Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Pregnancies in women with chronic diseases are often accompanied by concerns about potential complications [1]. This analysis explored medication-related concerns among women with inflammatory…
Abstract Number: 1634 • ACR Convergence 2023
Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
Benjamin A Fisher¹, Xavier Mariette², Athena S Papas³, Thomas Grader-Beck⁴, Hendrika Bootsma⁵, Wan-Fai Ng⁶, Paul Van Daele⁷, Stephanie Finzel⁸, Sergio Elgueta⁹, Josef Hermann¹⁰, Sara McCoy¹¹, Arthur Bookman¹², Monika Sopala¹³, Wen-Lin Luo¹⁴, Cornelia Scheurer¹³ and Wolfgang Hueber¹³, ¹University of Birmingham, Birmingham, United Kingdom, ²Université Paris-Saclay, Le Kremlin-Bicêtre, France, ³Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁴Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, ⁶NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁷Department of internal medicine, Erasmus MC, Rotterdam, Netherlands, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ⁹Clinical Research Chile SpA, Biomedical Research Centre, Valdivia, Chile, ¹⁰Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ¹¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ¹²Toronto Western Hospital, Toronto, ON, Canada, ¹³Novartis Pharma AG, Basel, Switzerland, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease affecting secretory glands and other organs with no approved systemic treatments. Iscalimab (CFZ533) is a mAb directed…
Abstract Number: 2030 • ACR Convergence 2023
Positive Psychosocial Factors May Protect Against Perceived Stress in a Multiethnic Cohort of People with SLE with and Without Trauma History
Kimberly DeQuattro¹, Laura Trupin², Sarah Patterson³, Stephanie Rush², Caroline Gordon⁴, Kurt Greenlund⁵, Kamil Barbour⁵, Cristina Lanata⁶, Lindsey Criswell⁷, Maria Dall'Era², Jinoos Yazdany² and Patti Katz⁸, ¹University of Pennsylvania, Media, PA, ²University of California San Francisco, San Francisco, CA, ³University of California San Francisco, Pacifica, CA, ⁴Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Centers for Disease Control and Prevention, Atlanta, GA, ⁶National Human Genome Research Institute, Washington, DC, ⁷NIH/NHGRI, Bethesda, MD, ⁸University of California San Francisco, San Rafael, CA
Background/Purpose: Trauma exposures are associated with SLE onset and disease activity; perceived stress is also associated with greater SLE disease activity and worse patient-reported outcomes.…
Abstract Number: 2234 • ACR Convergence 2023
Disagreement Between Patient and Physician Global Assessment over Time in Psoriatic Arthritis: Insight into Treatment Priorities
Proton Rahman¹, Laura Coates², Peter Nash³, Atul Deodhar⁴, Francois Nantel⁵, Emmanouil Rampakakis⁶, Louis Bessette⁷, A. Marilise Marrache⁸, Frederic Lavie⁹, May Shawi¹⁰ and William R Tillett¹¹, ¹Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ²University of Oxford, Oxford, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁵Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁶McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁷Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁸Janssen Inc., Rheumatology and Biologics, Dollard-des-Ormeaux, QC, Canada, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰Immunology, Janssen Research & Development, LLC, Titusville, NJ, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: The PsA core domain set developed by the Outcome Measures in Rheumatology working group includes musculoskeletal disease, fatigue, physical function, and structural damage, of…
Abstract Number: 0326 • ACR Convergence 2023
Assessment of Depression in Ankylosing Spondylitis Using Center for Epidemiologic Studies Depression Scale
Yvette Farran¹, Mark Hwang¹, John Reveille², Lianne Gensler³, Accelerating Medicines Partnership Program RA SLE Network⁴, Mariko Ishimori⁴ and Michael Ward⁵, ¹The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, ²The University of Texas Health Science Center, Houston, TX, ³University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints. Depression is a common comorbidity in AS patients…
Abstract Number: 0458 • ACR Convergence 2023
Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience
Maria Rodriguez Laguna¹, Zulema Rosales-Rosado², Cristina Vadillo-Font¹, Jose Pierre Otazu-Moudelle¹, Inés Pérez Sancristóbal¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone an enormous change in the last two decades with the use of biological Disease Modifying Drugs…
Abstract Number: 0721 • ACR Convergence 2023
Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica
Tonya K Marmon¹, Jason C Cole², Claire Owen³, Sarah Mackie⁴ and David Katz⁵, ¹Marmon Biostatistics, Seattle, WA, ²P3 Research Consulting, Torrance, CA, ³Austin Health, Malvern East, Australia, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: Pain, stiffness, and fatigue have been defined as core assessment domains in polymyalgia rheumatica (PMR) by the OMERACT PMR Working Group (PMRWG). Patient partners…
Abstract Number: 1211 • ACR Convergence 2023
Description of Self-Efficacy for Managing Symptoms and Emotions in a Large Rheumatology Clinic Population
Rachel Dayno¹, Michael George¹, Kimberly DeQuattro², Marissa Blum³, Sharon Kolasinski⁴ and Dana DiRenzo⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Pennsylvania, Cherry Hill, NJ, ⁴University of Pennsylvania, Philadephia, PA, ⁵University of Pennsylvania, Bala Cynwyd, PA
Background/Purpose: Self-efficacy (SE) is the inner belief in one's ability to succeed in specific situations and tasks. SE for managing the symptoms and emotions associated…
Abstract Number: 1368 • ACR Convergence 2023
Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Benjamin A Fisher¹, Linda Stone², Jessica Marvel³, Pushpendra Goswami⁴, Monia Steenackers⁴, Gayle Kenney⁴, Chiara Perella⁵, Wolfgang Hueber⁴, Chloe Howse⁶, Elizabeth Gargon⁶, Aishwarya Chohan⁶, Megan Mayhew⁶ and Nicola Williamson⁶, ¹University of Birmingham, Birmingham, United Kingdom, ²The British Sjogren’s Syndrome Association, Birmingham, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Riehen, Switzerland, ⁶Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom
Background/Purpose: Sjögren's is a heterogenous chronic auto-immune disease, characterized by excessive dryness of the eyes and mouth, as well as systemic complications which can significantly…
Abstract Number: 1839 • ACR Convergence 2023
Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting
Styliani Tsiami¹, Elena Enax-Krumova², Dietrich Sturm³, Matthias Vorgerd², Bjoern Buehring⁴, Juergen Braun⁵ and Xenofon Baraliakos¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Neurologische Klinik Universitätsklinikum Bergmannsheil Bochum, Ruhr-University Bochum, Bochum, Germany, ³Agaplesion Bethesda - Krankenhaus, Wuppertal, Klinik für Neurologie, Wuppertal, Germany, ⁴Krankenhaus St. Josef, Wuppertal, Klinik für Internistische Rheumatologie, Wuppertal, Germany, ⁵Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Small fiber neuropathy (SFN), a polyneuropathy (PNP) affecting A-delta and C-fibers has been described in patients with fibromyalgia (FM). Different patterns of small fiber…
Abstract Number: 2033 • ACR Convergence 2023
Sex Differences in Patient-Reported Outcomes in Patients with Rheumatoid Arthritis After Starting a New Disease-Modifying Antirheumatic Medication
John Davis¹, Sara Achenbach², Courtney Arment¹, Delamo Bekele¹, Vanessa Kronzer¹, Thomas Mason¹, Elena Myasoedova¹, Lynne Peterson¹, Kerry Wright¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Patient-Reported Outcome Measurement Information System (PROMIS®) measures are valued in the assessment of health outcomes for patients with rheumatoid arthritis (RA). However, little is…
Abstract Number: 2236 • ACR Convergence 2023
Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
Jeffrey R Curtis¹, Atul Deodhar², Enrique Soriano³, Emmanouil Rampakakis⁴, May Shawi⁵, Natalie shiff⁶, Marcie Strauss⁷, Chenglong Han⁸, William R Tillett⁹ and Dafna Gladman¹⁰, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷MEDASOURCE, Medical Group, Indianapolis, IN, ⁸Immunology, Janssen Global Services, LLC, Malvern, PA, ⁹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Guselkumab (GUS) has demonstrated robust efficacy across key PsA domains at Week (W) 24, with effects sustained or further enhanced through 2 years. Timing…
Abstract Number: 0330 • ACR Convergence 2023
Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement
Liam Harvey¹, Guy Katz², Yasmin Hernandez-Barco², Ana Fernandes², Aubree McMahon², Grace McMahon², Isha Jha², Zachary Wallace³, Cory Perugino² and John Stone⁴, ¹Frank H. Netter School of Medicine at Quinnipiac University, New Haven, CT, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: IgG4-Related Disease (IgG4-RD) is a systemic immune-mediated disease that commonly involves the pancreas in the form of autoimmune pancreatitis (AIP). Despite being one of…
Abstract Number: 0461 • ACR Convergence 2023
Self-esteem as a Determinant of Sexual Function in SLE Patients
María Espinosa-León¹, Daniela Marengo-Rodríguez², Monserrat Ibarra-Velasco², Ana Barrera-Vargas² and Javier Merayo-Chalico³, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, ³Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico
Background/Purpose: Rheumatic diseases, and specifically SLE, present with greater sexual dysfunction than other chronic diseases. Sexual dysfunction (SxD) is multifactorial and comprises disease-related factors, psychological…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].